lifestyle.washingtonguardian.com

Author: Telix Pharmaceuticals Limited

TLX101-Px (Pixlumi®) MAA Accepted in Europe

April 30, 2026
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

April 29, 2026
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

April 27, 2026
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

April 21, 2026
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

April 14, 2026
Telix and Regeneron Announce Strategic Radiopharma Collaboration

April 13, 2026
Telix Strengthens Board with Additional Director Appointments

April 8, 2026
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

April 7, 2026
Telix Appoints David Gill as Non-Executive Director

April 1, 2026
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate

March 15, 2026